In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%. In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's Natco Pharma to sell generic drug Nexavar,...
More »SEARCH RESULT
Natco Pharma bags licence to sell Bayer's cancer drug Nexavar
-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision. The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...
More »Natco Pharma bags licence to sell Bayer's cancer drug Nexavar
-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision. The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...
More »U.N. Human Rights Council Exhorted to Defend Peasants’ Rights by Isolda Agazzi
Decades after peasants’ networks have advocated for a new legal instrument to protect the rights of small farmers to land, seeds, traditional agricultural knowledge and freedom to determine the prices of their production, the United Nations Human Rights Council (UNHRC) may decide to start drafting a declaration on peasants’ rights next week. "The idea of an international declaration on peasants' rights comes from our (base) because many small farmers don’t have...
More »Novartis vs India: the showdown approaches by Simon Reid-Henry
The Swiss-based pharmaceutical giant Novartis is taking the state of India to court in a case that has, after rumbling about in the lower courts for six years, wound up as a very public litmus test of the legal framework sustaining India’s generic drugs revolution. With the case due before the Supreme Court on 28 March, the fate of millions who depend on affordable Indian medicines may soon hang in the...
More »